Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ovarian cancer
Biotech
Genmab discards ADC from $1.8B ProfoundBio buy
The discarded candidate, dubbed GEN1107, is a PTK7-targeted ADC that was being studied in a phase 1/2 solid tumor trial.
Gabrielle Masson
Sep 16, 2025 10:33am
PMV plots ovarian cancer filing after seeing midphase data
Sep 10, 2025 9:40am
Zymeworks drops clinical-stage TCE over benefit-risk profile
Sep 2, 2025 8:10am
Nuvectis axes ovarian cancer program after seeing phase 1b data
Jul 31, 2025 9:15am
BerGenBio, following lead drug's failure, merges with Oncoinvent
Jul 1, 2025 7:00am
Ernexa's stem cell therapy shrinks ovarian tumors in mice
Jun 2, 2025 2:30pm
